Celgene Loses Sanctions Bid Against Teva Unit In Patent Row

Law360, Miami (May 8, 2013, 9:10 PM EDT) -- A Florida federal judge on Wednesday denied Celgene Corp.'s bid to sanction a Teva Pharmaceutical Industries Ltd. unit for pursuing a patent infringement case involving Celgene's bone-marrow cancer drug Vidaza that Celgene calls “frivolous from the outset.”

Ruling from the bench, U.S. Magistrate Judge Lurana Snow declined to sanction Teva unit IVAX LLC, saying the lawsuit was not as clearly frivolous as Celgene made it appear.

“If I were to impose Rule 11 sanctions at this point, the Eleventh Circuit would see fit to send it...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.